About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

TLCR Chinese Edition more

免疫治疗是晚期非小细胞肺癌去化疗的关键,或还是未到时候?

免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)改变了缺乏驱动基因突变的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗... More >>

晚期或转移性非小细胞肺癌一线免疫治疗中,肿瘤细胞PD-L1表达的阈值究竟在哪

对于晚期或转移性非小细胞肺癌(non-small cell lung cancer,NSCLC),一线免疫治疗对部分患者来说,可以获得比单纯化疗更好的总生存率获益。 More >>

KEYNOTE-042研究:降低帕博利珠单抗单药一线治疗的PD-L1阈值是个好主意吗?

在针对程序性死亡1(programmed death 1,PD-1)或程序性死亡配体1(programmed death ligand 1,PD-L1)的抑制性抗体出现之前,晚期/转移性非小细胞肺癌(... More >>

Original Article

The impact of different modalities of chemoradiation therapy and chemotherapy regimens on lymphopenia in patients with locally advanced non-small cell lung cancer
Yaqi Li, Xingwen Fan, Yulei Pei, Qi Yu, Renquan Lu, Guoliang Jiang, Kailiang Wu
Segmentectomy versus lobectomy for ground-glass opacity dominant cT1N0 invasive lung adenocarcinoma
Zelin Ma, Yang Zhang, Han Han, Shengping Wang, Yuan Li, Haiquan Chen
Association between strenuous sports or other exercises and lung cancer risk: a mendelian randomization study
Wushu Chen, Anlin Liu, Yu Jiang, Yuechun Lin, Xingpei Li, Chongde Pan, Yixuan Wang, Huiwen Yu, Yulin Zhao, Junxing Li, Hengrui Liang, Runchen Wang, Wei Wang, Xin Xu, Ying Huang
Clinical impact of EGFR and KRAS mutations in surgically treated unifocal and multifocal lung adenocarcinoma
Jiahao Jiang, Mark F. Berry, Natalie S. Lui, Douglas Z. Liou, Winston L. Trope, Leah M. Backhus, Joseph B. Shrager
Predicting MET exon 14 skipping mutation in pulmonary sarcomatoid carcinoma by whole-tumour texture analysis combined with clinical and conventional contrast-enhanced computed tomography features
Lei Miao, Tian Qiu, Yan Li, Jianwei Li, Xu Jiang, Mengwen Liu, Xue Zhang, Jiuming Jiang, Huanhuan Zhang, Yanmei Wang, Xiao Li, Jianming Ying, Meng Li
Predictive value of delta-radiomic features for prognosis of advanced non-small cell lung cancer patients undergoing immune checkpoint inhibitor therapy
Xiaoyu Han, Yujin Wang, Xi Jia, Yuting Zheng, Chengyu Ding, Xiaohui Zhang, Kailu Zhang, Yunkun Cao, Yumin Li, Liming Xia, Chuansheng Zheng, Jing Huang, Heshui Shi
Heterogeneity of lymphocyte subsets in predicting immune checkpoint inhibitor treatment response in advanced lung cancer: an analysis across different pathological types, therapeutic drugs, and age groups
Chuanwang Miao, Yuanji Chen, Hao Zhang, Wei Zhao, Cunliang Wang, Zeliang Ma, Shan Zhu, Xudong Hu
Bioinformatics analysis of an immunotherapy responsiveness-related gene signature in predicting lung adenocarcinoma prognosis
Yupeng Jiang, Bacha Hammad, Hong Huang, Chenzi Zhang, Bing Xiao, Linxia Liu, Qimi Liu, Hengxing Liang, Zhenyu Zhao, Yawen Gao
Correlation analysis between driver gene mutation and clinicopathological features in lung adenocarcinoma based on real-world cumulative clinical data
Sheng Lu, Aotian Guo, Haichuan Hu, Xinxin Ying, Yao Li, Zhengwei Huang, Wangjue Xu, Shen Tao, Xiaotong Hu, Na Yan, Xuan Zhang, Dan Shen, Takaaki Sasaki, Surein Arulananda, Ken Onodera, Zhengfu He
The prognostic role of albumin levels in lung cancer patients receiving third-line or advanced immunotherapy: a retrospective study
Yanfei Chen, Tong Liu, Hui Feng, Tiantian Liu, Jing Zhang, Jun Wang, Jihong Lu, Antonio Rossi, Ivy Riano, Pingping Hu, Jiandong Zhang
Predicting complication risks after sleeve lobectomy for non-small cell lung cancer
Yiming He, Lin Huang, Jiajun Deng, Yifan Zhong, Tao Chen, Yunlang She, Lei Jiang, Deping Zhao, Dong Xie, Gening Jiang, Stefano Bongiolatti, Mara B. Antonoff, René Horsleben Petersen, Chang Chen
PSME3 promotes lung adenocarcinoma development by regulating the TGF-β/SMAD signaling pathway
Shuai Wang, Yongmeng Li, Kai Jin, Kenichi Suda, Rongyang Li, Huiying Zhang, Hui Tian
Peptidyl-prolyl isomerase F as a prognostic biomarker associated with immune infiltrates and mitophagy in lung adenocarcinoma
Zitong Feng, Lin Yuan, Luyuan Ma, Wenhao Yu, Fayez Kheir, Lukas Käsmann, Wolfgang M. Brueckl, Kai Jin, Dingxin Wang, Yi Shen, Rongyang Li, Hui Tian
Tumor mutation burden and FAT3 mutation influence long-term survival in surgically resected small cell lung cancer
Xinyu Qian, Lin Zhu, Na Han, Jing Qin
Pathological and imaging features of pulmonary invasive mucinous adenocarcinoma—a retrospective cohort study
Xinfu Pan, Renxiu Fang, Binjie Zhang, Zhijun Chen, Shanhua Zhang, Hanbo Le, Helmut H. Popper, Lu Liu, Yongkui Zhang

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
Bryan A. Chan, Brett G.M. Hughes
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto
Global trends of lung cancer mortality and smoking prevalence
Farhad Islami, Lindsey A. Torre, Ahmedin Jemal
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao
Tackling ALK in non-small cell lung cancer: the role of novel inhibitors
Francesco Facchinetti, Marcello Tiseo, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello
Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?
Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Jeryl Villadolid, Asim Amin

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis
Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song
BRAF mutations in non-small cell lung cancer
Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper
The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer
Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper
Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice
Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song
Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song
Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer
Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen
The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants
Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden
The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices
Abdulhamid Chaikh, Jacques Balosso

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto
Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement
Hyojin Kim, Jin-Haeng Chung
Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer
Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao
Clinical trials for lung cancer in China
Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu
Recurrence after surgery in patients with NSCLC
Hidetaka Uramoto, Fumihiro Tanaka
Prognostic markers in lung cancer: is it ready for prime time?
Chang-Qi Zhu, Ming-Sound Tsao
Potential biomarkers for lung cancer screening
Gabriella Sozzi, Mattia Boeri
Particle therapy in non-small cell lung cancer
Zhongxing Liao, Charles B. Simone II
Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions
Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai
Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer
Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft
Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors
Suchit H. Patel, Andreas Rimner, Roger B. Cohen
Intraoperative near-infrared imaging of mesothelioma
Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal
BAP1, a tumor suppressor gene driving malignant mesothelioma
Mitchell Cheung, Joseph R. Testa
Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation
Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update
Zhongjian Chen, Giovanni Gaudino, Harvey I. Pass, Michele Carbone, Haining Yang
Immunotherapy for malignant pleural mesothelioma: current status and future directions
Jordan Dozier, Hua Zheng, Prasad S. Adusumilli
Biology and clinical significance of circulating tumor cell subpopulations in lung cancer
Linda O’Flaherty, Harriet Wikman, Klaus Pantel
Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?
Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Cyril Catelain, Françoise Farace
Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer
Sumitra Mohan, Francesca Chemi, Ged Brady
Biophysical technologies for understanding circulating tumor cell biology and metastasis
Derrick W. Su, Jorge Nieva
Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer
Marianna Gallo, Antonella De Luca, Monica Rosaria Maiello, Amelia D’Alessio, Claudia Esposito, Nicoletta Chicchinelli, Laura Forgione, Maria Carmela Piccirillo, Gaetano Rocco, Alessandro Morabito, Gerardo Botti, Nicola Normanno
Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer
Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis
Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

Editorials

Dulanermin in cancer therapy: Still much to do
Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data
Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner
Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung
Pedro Mendez, Jose Luis Ramirez
Role of HGF/MET axis in resistance of lung cancer to contemporary management
Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr
Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review
Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack
Lorenza Landi, Federico Cappuzzo

Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer

Biology of invasive mucinous adenocarcinoma of the lung
Yoon Jin Cha, Hyo Sup Shim
Immunohistochemistry for predictive biomarkers in non-small cell lung cancer
Mari Mino- Kenudson

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.